In summary, BET proteins are the important upstream regulators of MYCN and inhibiting BET proteins by the BET inhibitors alone or combined with other therapeutic strategies might be efficient methods to inhibit NB development by attenuating the expression of MYCN. In addition, exploring the new inhibitors of BET family proteins and the novel combined therapeutic strategies have made valuable contributions to the treatment of NB patients. The gene discussed is DNER; the disease is neuroblastoma.